开发并验证包含校正QT间期的评分系统用于肝硬化合并消化道出血患者的风险分析
在意大利274例肝硬化急性消化道出血患者中建立6周死亡风险评分(MELDNa-AGIB),纳入QTc>456 ms、MELD-Na评分、既往出血史和血清白蛋白。在200例验证集中,该评分识别6周死亡的AUROC为0.888,高于MELD、Child-Turcotte-Pugh、D'Amico和Augustin评分。
要点
- QTc>456 ms、MELD-Na评分、既往出血和血清白蛋白与6周死亡独立相关。
- MELDNa-AGIB评分在验证集中识别6周死亡的AUROC为0.888,高于MELD评分0.838。
- 训练集中MELDNa-AGIB评分≤4分者6周死亡率仅6.3%,≥25分者达81%以上。
核心结论
- QTc是肝硬化急性消化道出血患者6周死亡的独立预测因素,MELDNa-AGIB评分可准确判断6周死亡风险。
研究设计与样本
- 训练集为2001年1月至2012年12月意大利博洛尼亚一家医院收治的274例肝硬化急性消化道出血患者。
- 验证集为意大利2家独立医院2001年至2016年及2007年至2012年收治的200例肝硬化消化道出血患者。
主要发现
- 训练集中QTc>456 ms、MELD-Na评分、既往出血和血清白蛋白与6周死亡独立相关。
- 验证集中MELDNa-AGIB识别6周死亡的AUROC为0.888,高于MELD评分0.838(P=0.031)。
- 验证集中MELDNa-AGIB的AUROC高于更新校准MELD评分0.837(P=0.029)、Child-Turcotte-Pugh评分0.789(P=0.004)、D'Amico评分0.761(P=0.003)和Augustin评分0.792(P=0.001)。
- 验证集中MELDNa-AGIB的净重分类改善优于MELD-Na评分0.266(P=0.045)。
- 校准方面MELDNa-AGIB的Hosmer-Lemeshow检验P=0.947,优于MELD-Na的P=0.146。
关键数值与推荐
- MELDNa-AGIB评分纳入QTc>456 ms、MELD-Na评分、既往出血和血清白蛋白浓度。
- 训练集MELDNa-AGIB评分≤4分者6周死亡率为6.3%。
- 训练集MELDNa-AGIB评分9分者6周死亡率为15.5%。
- 训练集MELDNa-AGIB评分16分者6周死亡率为41.5%。
- 训练集MELDNa-AGIB评分≥25分者6周死亡率为81%以上。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The electrocardiographic QT interval frequently is prolonged in patients with cirrhosis. Acute gastrointestinal bleeding further prolongs corrected QT (QTc) in patients with cirrhosis, which has been associated with an increased risk of death within 6 weeks. We aimed to confirm these findings and develop a mortality risk index that incorporates QTc. METHODS: We collected data from 274 patients with cirrhosis and acute gastrointestinal bleeding from any cause admitted to a hospital in Bologna, Italy, from January 2001 through December 2012 (training set). We used logistic regression analysis to identify patient factors associated with death within 6 weeks (6-week mortality). We validated our findings by using data from 200 patients with cirrhosis and gastrointestinal bleeding treated at 2 separate hospitals in Italy, from 2001 through 2016 and 2007 through 2012. Our primary aim was to confirm the prognostic effects of prolonged QTc in a large population of patients and develop a 6-week mortality risk score for acute gastrointestinal bleeding from any cause that incorporates the QTc interval. RESULTS: In the training set, QTc greater than 456 ms, the model for end-stage liver disease-sodium (MELD-Na) score, previous bleeding, and serum albumin concentration were associated independently with 6-week mortality. We combined these parameters to create a risk scoring system that we named MELD-Na acute gastrointestinal bleeding (MELDNa-AGIB). In the validation set, the MELDNa-AGIB identified patients who died within 6 weeks with an area under the receiver operating characteristic curve (AUROC) of 0.888; this value was higher than that of the MELD score (AUROC, 0.838; P = .031), MELD score with updated calibration (AUROC, 0.837; P = .029), Child-Turcotte-Pugh score (AUROC, 0.789; P = .004), D'Amico score (AUROC, 0.761; P = .003), and Augustin score (AUROC, 0.792; P = .001), with a net reclassification improvement better than the MELD-Na score (0.266; P = .045). In calibration, the MELDNa-AGIB produced a high score in the Hosmer-Lemeshow test (P = .947), which was superior to that of MELD-Na (P = .146). In the training set, only 6.3% of patients with MELDNa-AGIB scores of 4 or less died within 6 weeks. Among patients with a scores of 9, 16, and 25 or higher, 15.5%, 41.5%, and 81% or more patients died within 6 weeks, respectively. The probability of survival progressively and significantly decreased with increasing scores in the training and validation sets. CONCLUSIONS: We confirmed QTc as an independent predictor of 6-week mortality in a large population of patients with cirrhosis and acute gastrointestinal bleeding. The combination of QTc, MELD-Na, previous bleeding, and serum albumin (the MELDNa-AGIB score) accurately determines the risk of 6-week mortality, providing timely identification of patients at very high risk of death.
引用
- Biselli M, Gramenzi A, Lenzi B, et al. Development and Validation of a Scoring System That Includes Corrected QT Interval for Risk Analysis of Patients With Cirrhosis and Gastrointestinal Bleeding. Clin Gastroenterol Hepatol. 2018. PMID: 30557740. doi:10.1016/j.cgh.2018.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。